Promising Results from DMT Therapy for Depression

A recent phase II clinical trial has indicated that dimethyltryptamine (DMT), a psychoactive component traditionally used in the Amazonian psychedelic ritual ayahuasca, may serve as an effective therapy for depression. The trial, sponsored and designed by the psychedelic pharmaceutical company Small Pharma (now Cybin UK), was led by Dr. David Erritzoe, a psychiatrist and neuroscientist at Imperial College London. The study involved 34 participants, with 17 receiving a DMT injection and 17 receiving a placebo, all accompanied by psychotherapeutic support. Results published in *Nature* revealed that those administered DMT experienced a more significant reduction in depressive symptoms compared to the placebo group two weeks post-injection.

The Guardian

Tommaso Barba, a PhD candidate at Imperial College London and one of the study's authors, emphasized the importance of therapeutic support in the trial. He noted that therapists played a crucial role in preparing participants for the psychedelic experience and assisting them in integrating the experience into their lives afterward. Barba cautioned that the trial was small and preliminary, stating, “There’s still more to do, but it’s promising.”

The Guardian

Traditional ayahuasca involves consuming a tea made from plants containing psychedelic components, often resulting in nausea and vomiting. In contrast, the synthetic DMT formulation used in the trial produces a brief, intense 30-minute psychedelic experience without inducing vomiting. Dr. Daniel Perkins, a senior research fellow at the University of Melbourne, acknowledged that while vomiting can have cathartic effects in traditional ayahuasca experiences, it did not significantly impact overall benefits in the study.

The Guardian

The U.S. Food and Drug Administration (FDA) previously approved Spravato, a ketamine-based nasal spray, for treatment-resistant depression in 2019, marking the first psychedelic-adjacent depression treatment to receive FDA approval. Ongoing trials for other substances, including psilocybin and MDMA, are also being explored. However, the FDA declined to approve MDMA-assisted therapy for PTSD due to ethical concerns and data reliability issues. Perkins suggested that psychedelics like psilocybin and DMT may offer therapeutic benefits even outside clinical settings, unlike recreational MDMA.

The Guardian

Despite the promising results, Barba highlighted several challenges facing the implementation of DMT therapy. The FDA regulates drugs rather than therapies, which may lead pharmaceutical companies to minimize therapeutic components in future treatments. Additionally, the requirement for DMT to be administered in a clinical setting via injection may not appeal to all patients, especially compared to more accessible oral medications. Barba noted that DMT should not be viewed as a "quick fix" for depression, as it often serves as a catalyst for deeper personal insights and necessary life changes.

The Guardian

• “There’s still more to do, but it’s promising,” — Tommaso Barba, PhD Candidate, Imperial College London

The Guardian

• “In our research, people do report that vomiting can have quite psychologically, emotionally cathartic effects,” — Dr. Daniel Perkins, Senior Research Fellow, University of Melbourne

The Guardian

• “It can act as a catalyst,” — Tommaso Barba, PhD Candidate, Imperial College London

The Guardian

The findings from this trial suggest a potential new avenue for depression treatment, although further research and regulatory considerations will be essential for its future application.

The Guardian